Aerovate Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
A group of investment entities, including Venrock Healthcare Capital Partners, has reported a combined beneficial ownership of 8.3% in Jade Biosciences, Inc. as of June 30, 2026.
Bellevue Group AG and its subsidiary Bellevue Asset Management AG have reported beneficial ownership of 5.0% of Jade Biosciences, Inc. common stock.
Paradigm BioCapital Advisors LP, along with affiliated entities, has reported beneficial ownership of over 5% of Jade Biosciences, Inc. common stock.
Janus Henderson Group Ltd. has reported beneficial ownership of 10.6% of Jade Biosciences, Inc. common stock, totaling 6,273,262 shares, as of June 30, 2026.
Janus Henderson Group plc has reported beneficial ownership of 3,105,669 shares, representing 6.3% of the outstanding common stock of Jade Biosciences, Inc.
Janus Henderson Group plc has reported a 6.2% beneficial ownership stake in JADE BIOSCIENCES, INC., holding over 3 million shares as of December 31, 2025.
Deep Track Capital and its affiliates have reported a complete divestment of their beneficial ownership in Jade Biosciences, Inc.
The Vanguard Group has filed an amended Schedule 13G, disclosing a 4.24% beneficial ownership stake in Jade Biosciences Inc. as of December 31, 2025.
SCHEDULE 13G/A: Frazier Life Sciences Group Amends Jade Biosciences Stake
Frazier Life Sciences and affiliated entities filed an amended Schedule 13G, disclosing a collective beneficial ownership of approximately 4.33% in Jade Biosciences, Inc.
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, reported a 6.99% beneficial ownership stake in Jade Biosciences, Inc. as of September 30, 2025.
SCHEDULE 13G/A: BlackRock Discloses 6.6% Stake in Jade Biosciences
BlackRock, Inc. has reported a 6.6% beneficial ownership in JADE BIOSCIENCES INC, holding 2,150,203 shares of common stock as of September 30, 2025.
RA Capital Management and its affiliates have reported a 7.0% beneficial ownership stake in Jade Biosciences, Inc., holding 3,214,969 shares.
Frazier Life Sciences and its affiliates filed an amended Schedule 13G, clarifying their beneficial ownership in Jade Biosciences, Inc. common stock.
The Vanguard Group has reported a passive beneficial ownership of 5.6% in Jade Biosciences Inc., holding 1,807,582 shares of common stock.
SCHEDULE 13G: BlackRock Discloses 5.3% Stake in Jade Biosciences
BlackRock, Inc. has filed a Schedule 13G, reporting a beneficial ownership of 5.3% of Jade Biosciences, Inc.'s common stock as of June 30, 2025.
Deep Track Capital, LP, along with its affiliates Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 8.64% in Jade Biosciences, Inc. common stock.
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a significant beneficial ownership stake of 14.7% in Jade Biosciences Inc., totaling 4,735,951 common shares.
TCG Crossover GP I, LLC, TCG Crossover Fund I, L.P., and Chen Yu have jointly filed an amendment to their Schedule 13G, reporting a beneficial ownership of 0.2% in Jade Biosciences, Inc.'s common stock.
SCHEDULE 13G: Venrock Affiliates Disclose 9.9% Stake in Jade Biosciences, Inc. via Schedule 13G Filing
A group of Venrock Healthcare Capital Partners entities and individuals have disclosed a collective 9.9% beneficial ownership stake in Jade Biosciences, Inc., as detailed in a recent Schedule 13G filing.
A group of affiliated entities and individuals led by Frazier Life Sciences has disclosed beneficial ownership exceeding 5% in Jade Biosciences, Inc. common stock.